Migraine is a neurological condition characterized by moderate to severe headaches; it can have a major impact on patients’ quality of life. Our quantitative analysis of treatment patterns focuses specifically on the prophylactic treatment of migraine, aimed at preemptively reducing the frequency, severity, and duration of future migraine attacks and, in turn, reducing patients’ level of disability and potentially increasing the responsiveness of breakthrough migraine attacks to acute treatment. Although generic AEDs, antidepressants, and beta blockers dominate the first three lines of therapy, our report provides insight on both the market-leading classes and the uptake of newer-to-market classes, such as CGRP monoclonal antibodies and the CGRP-targeted oral therapy Qulipta (AbbVie). Please note that we do not include Pfizer’s Nurtec ODT in our main analysis as we cannot easily parse out acute use of the drug from its prophylactic use.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States.
Key companies: Amgen, Novartis, Eli Lilly, Teva, Lundbeck, and AbbVie.
Key drugs: Aimovig, Emgality, Ajovy, Vyepti, Qulipta, Botox, topiramate IR, topiramate XR, Trokendi XR, amitriptyline, propranolol.
The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.